Liver mass pathophysiology

Jump to: navigation, search

Liver Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Evaluation of Liver Mass

Staging

History and Symptoms

Physical Examination

Laboratory Studies

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Liver mass pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liver mass pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liver mass pathophysiology

CDC on Liver mass pathophysiology

Liver mass pathophysiology in the news

Blogs on Liver mass pathophysiology

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Liver mass pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

The exact pathogenesis of a liver mass depends upon the underlying disease. Increased estrogen in hepatic adenoma stimulates hepatocytes via steroid receptors and results vascular ectasia. While in FNH excessive release of growth factors promote growth of small arteries. Some conditions such as hemangioma, hepatic cysts are believed to be as result of genetic abnormality. Precancerous lesions are responsible for HCC, cholangiosarcoma. Hepatic abscess and echinoccosiosis are due to infectious agents.

Pathophysiology

The exact pathogenesis of a liver mass depends upon the underlying disease. The following table summarizes the various causes of liver masses:

Disease Pathogenesis Genetics Associated Conditions Gross Pathology Microscopic Pathology
Hepatocellular adenoma
  • Estrogens cause the transformation of hepatocytes via steroid receptors
  • Results in generalized vascular ectasia
  • Transcription factor 1 gene (TCF1)
  • Interleukin 6 signal transducer gene (IL6ST)
  • β catenin-1 gene (CTNNB1)
  • Well circumscribed
  • Non-lobulated
  • Smooth and soft
  • White to yellow to brown lesions
Focal nodular hyperplasia
  • β-catenin gene (CTNNB1)
  • TP53
  • APC or HNF1α
  • Klippel-Trénaunay-Weber syndrome
  • Well-circumscribed
  • Non-encapsulated
  • Central fibrous scar
  • Hepatic parenchyma arranged in incomplete nodules
  • Fibrous tissue with thick-walled vessels
  • Bile ductular proliferation
  • Cells of chronic inflammation
Hemangioma
  • Congenital disorder
  • Vascular malformations that enlarge by ectasia 
  • Estrogen and progesterone influence over tumor growth
  • More common in females
  • Von Hippel Lindau disease
  • Well-circumscribed
  • Appear red-brown
  • Solitary nodules
  • Less than 5cms
  • Large cystically dilated vessels
  • Thin walls
  • Intravascular thrombosis
  • Calcifications
Hepatic Cyst
  • Von Meyenburg complexes separate from biliary tree and dilate to form cyst
  • Single, unilocular cyst
  • Variable amounts of clear amber fluid (may contain blood, bile, mucus, pus)
  • Lined by flat / cuboidal epithelium
  • Epithelium rests on thin collagenous wall without spindle cell stroma
  • Degenerative changes include epithelial desquamation, multiloculation, calcification
Lymphangioma
  • Lymphangioma is caused by either sequestration of
    • Lymph tissue
    • Abnormal budding of lymph vessels
    • Lack of fusion with the venous system,
    • Obstruction of lymph vessels.
  • Grey-white mass
  • Well circumscribed
  • Edematous appearance
  • Variable size (may be massive)
  • Filled with serous fluid
  • Smooth inner lining
Angiomyolipoma
  • Well circumscribed
  • Uniform yellow mass
Hepatocellular carcinoma
  • Arises from precancerous lesions.[1]:

[2][3][4][5][6][7]

    • Genomic alterations
    • Epigenetic modifications
    • Growth factor pathway alterations
  • Nodular or diffusely infiltrative
  • Pale in relation to surrounding liver or green
  • Large polygonal tumours cells
  • Graunular eosinophilic cytoplasm
  • Layered dense collagen bundles
Cholangiocarcinoma
  • The epithelial cell lining the bile ducts are called cholangiocytes.
  • The malignant transformsation of cholangiocytes leads to cholangiocarcinoma.[8]
  • Malignant transformation of cholangiocytes into cholangiocarcinoma include following stages:[9]
  • Hyperplasia
  • Metaplasia
  • Dysplasia
  • Frank carcinoma
  • Progression of malignancy is believed to be due to:[9][10][11]
    • Inflammation
    • Obstruction of bile ducts
    • Biliary intraepithelia neoplasia.
  • ARID1A
  • BAP1
  • BRAF
  • FGFR2
  • IDH1
  • IDH2
  • KMT2C
  • KRAS
  • PBRM1
  • PEG3
  • PTPN3
  • RNF43
  • ROBO2
  • SMAD4
  • TERT
  • TP53
  • Mass-forming
    • Nodular lesion or mass in the hepatic parenchyma
    • Gray to gray-white, firm and solid carcinoma
  • Periductal infiltrating
    • Spreading of the carcinoma along the portal tracts with stricture of the affected bile ducts
    • Dilatation of the peripheral bile ducts
  • Intraductal growth types
    • Polypoid or papillary tumor within the variably dilated bile duct lumen
    • Malignant progression of an intraductal papillary neoplasm of the bile duct
  • Cuboidal or columnar mucin producing cells
  • Dense fibrous(desmoplastic) stroma.
Hepatic abscess
Parasitic cysts:[18][19][20](Echinococcous)
  • Cysts tend to be:
    • Filled with clear fluid
    • White appearance
    • Solitary
    • Unilocular
  • Cyst wall composed of an acellular laminated external layer and a thin, germinal (nucleated) inner layer
  • Brood capsule with protoscoleces inside

References

  1. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J (2012). "Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma". Nat. Genet. 44 (6): 694–8. doi:10.1038/ng.2256. PMC 3819251. PMID 22561517.
  2. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih I, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013). "TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal". Proc. Natl. Acad. Sci. U.S.A. 110 (15): 6021–6. doi:10.1073/pnas.1303607110. PMC 3625331. PMID 23530248. Vancouver style error: initials (help)
  3. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J, Zucman Rossi J (2013). "High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions". Nat Commun. 4: 2218. doi:10.1038/ncomms3218. PMC 3731665. PMID 23887712.
  4. Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu HC, Lai PL, Yuan RH (2014). "TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection". Int J Surg. 12 (7): 659–65. doi:10.1016/j.ijsu.2014.05.066. PMID 24866078.
  5. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J (2015). "Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets". Nat. Genet. 47 (5): 505–511. doi:10.1038/ng.3252. PMC 4587544. PMID 25822088.
  6. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H, Yamamoto S, Shinbrot E, Hama N, Lehmkuhl M, Hosoda F, Arai Y, Walker K, Dahdouli M, Gotoh K, Nagae G, Gingras MC, Muzny DM, Ojima H, Shimada K, Midorikawa Y, Goss JA, Cotton R, Hayashi A, Shibahara J, Ishikawa S, Guiteau J, Tanaka M, Urushidate T, Ohashi S, Okada N, Doddapaneni H, Wang M, Zhu Y, Dinh H, Okusaka T, Kokudo N, Kosuge T, Takayama T, Fukayama M, Gibbs RA, Wheeler DA, Aburatani H, Shibata T (2014). "Trans-ancestry mutational landscape of hepatocellular carcinoma genomes". Nat. Genet. 46 (12): 1267–73. doi:10.1038/ng.3126. PMID 25362482.
  7. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS, Parker JS, Li J, Powers S, Kim H, Fischer S, Guindi M, Ghanekar A, Chiang DY (2013). "Identification of driver genes in hepatocellular carcinoma by exome sequencing". Hepatology. 58 (5): 1693–702. doi:10.1002/hep.26540. PMC 3830584. PMID 23728943.
  8. Fava, G.; Lorenzini, I. (2012). "Molecular Pathogenesis of Cholangiocarcinoma". International Journal of Hepatology. 2012: 1–7. doi:10.1155/2012/630543. ISSN 2090-3448.
  9. 9.0 9.1 Sirica A (2005). "Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy". Hepatology. 41 (1): 5–15. PMID 15690474.
  10. Holzinger F, Z'graggen K, Büchler M. "Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma". Ann Oncol. 10 Suppl 4: 122–6. PMID 10436802.
  11. Gores G (2003). "Cholangiocarcinoma: current concepts and insights". Hepatology. 37 (5): 961–9. PMID 12717374.
  12. Stain SC, Yellin AE, Donovan AJ, Brien HW (1991). "Pyogenic liver abscess. Modern treatment". Arch Surg. 126 (8): 991–6. PMID 1863218.
  13. Munro JC (1905). "VII. Lymphatic and Hepatic Infections Secondary to Appendicitis". Ann Surg. 42 (5): 692–734. PMC 1425980. PMID 17861705.
  14. Huang CJ, Pitt HA, Lipsett PA, Osterman FA, Lillemoe KD, Cameron JL; et al. (1996). "Pyogenic hepatic abscess. Changing trends over 42 years". Ann Surg. 223 (5): 600–7, discussion 607-9. PMC 1235191. PMID 8651751.
  15. Rahimian J, Wilson T, Oram V, Holzman RS (2004). "Pyogenic liver abscess: recent trends in etiology and mortality". Clin Infect Dis. 39 (11): 1654–9. doi:10.1086/425616. PMID 15578367.
  16. https://librepathology.org/wiki/Liver_pathology Accessed on February 22, 2017
  17. Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL; et al. (2002). "Hepatic abscess in patients with chronic granulomatous disease". Ann Surg. 235 (3): 383–91. PMC 1422444. PMID 11882760.
  18. Tappe, Dennis, August Stich, and Matthias Frosch. "Emergence of Polycystic Neotropical Echinococcosis." Emerging Infectious Disease 14.2 (2008): 292-97. Web. 21 February 2010.
  19. Howorth, MB. "Echinococcosis Of Bone." Journal of Bone and Joint Surgery 27. (1945): 401-11. Web. 21 February 2010.
  20. Cox FE (2002). "History of human parasitology". Clin. Microbiol. Rev. 15 (4): 595–612. PMC 126866. PMID 12364371.

Linked-in.jpg